IGC Pharma Announces Patient Enrollment at Toronto’s Baycrest in Phase 2 Trial Investigating IGC-AD1 October 17, 2024 Read More »
IGC Pharma Wins 2 Awards in Phase 1 of NIA’S AI PREPARE Challenge, Advancing Alzheimer’s Early Prediction Research October 17, 2024 Read More »
IGC Pharma Announces Additional Data Supporting IGC-AD1 as an Alzheimer’s Treatment September 18, 2024 Read More »